Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study
Identifieur interne : 002187 ( Main/Exploration ); précédent : 002186; suivant : 002188Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study
Auteurs : H. Przuntek ; D. Welzel [Allemagne] ; M. Gerlach ; E. Blümner [Allemagne] ; W. Danielczyk [Autriche] ; -J. Kaiser ; H. Kraus ; H. Letzel [Allemagne] ; P. Riederer ; K. Überla [Allemagne]Source :
- Journal of Neural Transmission [ 0300-9564 ] ; 1996-06-01.
Abstract
Summary: Long-term levodopa treatment in Parkinson's disease is typically associated with “motor side effects” consisting in dyskinesias and/or fluctuations in motility referred to as the on-off phenomena. The main objective of this prospective, randomized, multi-centre study was to determine to what extent the development of such complications could be prevented by partial substitution of levodopa monotherapy (L-DOPA/benserazide) by bromocriptine in patients with early symptoms of the disease. The basic trial population included 674 newly diagnosed Parkinsonian patients that were randomly allocated to monotherapy with levodopa or a combination therapy based upon a nearly 40% replacement of levodopa by bromocriptine. The two target regimens had to be consistently maintained for 42 months. Parkinsonian symptoms were assessed by means of the Webster rating scale, the Hoehn and Yahr scale, and the Zung Self-Rating Depression scale. Motor side effects and adverse events were recorded at each regular clinic visit. Neurological symptoms improved and stabilized in a similar manner during treatment with both regimens throughout the study period. Motor side effects were observed in more patients on levodopa alone than on combination therapy (28.8 vs 20%; p=0.008). According to Kaplan-Meier estimates the cumulative probability of experiencing motor side effects was 0.43 on monotherapy, compared to 0.28 on combination therapy, which was equal to a one third reduction of risk (p=0.025). In regard to motor side effects, the degree of substitution of levodopa proved relevant: patients with >50% substitution by bromocriptine exhibited half the risk observed in those with <30% (p=0.045). The overall burden of motor side effects, as reflected by a sum score based upon the relevance, the severity and the extent of motor dysfunction, was also significantly less on combination therapy (p=0.046). In conclusion, partial substitution of levodopa by bromocriptine (>30%) as first-line treatment of Parkinson's disease proves active in the prophylaxis of levodopa associated motor side effects. Early combination therapy therefore extends the period of optimal disease control.
Url:
DOI: 10.1007/BF01271230
Affiliations:
- Allemagne, Autriche
- Bavière, District de Haute-Bavière, Vienne (Autriche)
- Munich, Vienne (Autriche)
- Université Louis-et-Maximilien de Munich
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study</title><author><name sortKey="Przuntek, H" sort="Przuntek, H" uniqKey="Przuntek H" first="H." last="Przuntek">H. Przuntek</name></author><author><name sortKey="Welzel, D" sort="Welzel, D" uniqKey="Welzel D" first="D." last="Welzel">D. Welzel</name></author><author><name sortKey="Gerlach, M" sort="Gerlach, M" uniqKey="Gerlach M" first="M." last="Gerlach">M. Gerlach</name></author><author><name sortKey="Blumner, E" sort="Blumner, E" uniqKey="Blumner E" first="E." last="Blümner">E. Blümner</name></author><author><name sortKey="Danielczyk, W" sort="Danielczyk, W" uniqKey="Danielczyk W" first="W." last="Danielczyk">W. Danielczyk</name></author><author><name sortKey="Kaiser, J" sort="Kaiser, J" uniqKey="Kaiser " first="-J." last="Kaiser">-J. Kaiser</name></author><author><name sortKey="Kraus, H" sort="Kraus, H" uniqKey="Kraus H" first="H." last="Kraus">H. Kraus</name></author><author><name sortKey="Letzel, H" sort="Letzel, H" uniqKey="Letzel H" first="H." last="Letzel">H. Letzel</name></author><author><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name></author><author><name sortKey="Uberla, K" sort="Uberla, K" uniqKey="Uberla K" first="K." last="Überla">K. Überla</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C1B49CBEEDEF204DF74573AD4429D84F056BF7FC</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1007/BF01271230</idno><idno type="url">https://api.istex.fr/document/C1B49CBEEDEF204DF74573AD4429D84F056BF7FC/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B96</idno><idno type="wicri:Area/Main/Curation">000A49</idno><idno type="wicri:Area/Main/Exploration">002187</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study</title><author><name sortKey="Przuntek, H" sort="Przuntek, H" uniqKey="Przuntek H" first="H." last="Przuntek">H. Przuntek</name><affiliation><wicri:noCountry code="subField">Bochum</wicri:noCountry></affiliation></author><author><name sortKey="Welzel, D" sort="Welzel, D" uniqKey="Welzel D" first="D." last="Welzel">D. Welzel</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institut für Pharmakologie, Universität Regensburg</wicri:regionArea><wicri:noRegion>Universität Regensburg</wicri:noRegion><wicri:noRegion>Universität Regensburg</wicri:noRegion></affiliation></author><author><name sortKey="Gerlach, M" sort="Gerlach, M" uniqKey="Gerlach M" first="M." last="Gerlach">M. Gerlach</name><affiliation><wicri:noCountry code="subField">Bochum</wicri:noCountry></affiliation><affiliation><wicri:noCountry code="subField">Würzburg</wicri:noCountry></affiliation></author><author><name sortKey="Blumner, E" sort="Blumner, E" uniqKey="Blumner E" first="E." last="Blümner">E. Blümner</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Staticon, Medizinische Forschungsgesellschaft mbH, Planegg</wicri:regionArea><wicri:noRegion>Planegg</wicri:noRegion><wicri:noRegion>Planegg</wicri:noRegion></affiliation></author><author><name sortKey="Danielczyk, W" sort="Danielczyk, W" uniqKey="Danielczyk W" first="W." last="Danielczyk">W. Danielczyk</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>Neurologische Abteilung, Pflegeheim der Stadt Wien-Lainz, Ludwig-Boltzmann-Institut für Altersforschung, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Kaiser, J" sort="Kaiser, J" uniqKey="Kaiser " first="-J." last="Kaiser">-J. Kaiser</name><affiliation><wicri:noCountry code="subField">Nuremberg</wicri:noCountry></affiliation></author><author><name sortKey="Kraus, H" sort="Kraus, H" uniqKey="Kraus H" first="H." last="Kraus">H. Kraus</name><affiliation><wicri:noCountry code="subField">Bochum</wicri:noCountry></affiliation></author><author><name sortKey="Letzel, H" sort="Letzel, H" uniqKey="Letzel H" first="H." last="Letzel">H. Letzel</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Staticon, Medizinische Forschungsgesellschaft mbH, Planegg</wicri:regionArea><wicri:noRegion>Planegg</wicri:noRegion><wicri:noRegion>Planegg</wicri:noRegion></affiliation></author><author><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name><affiliation><wicri:noCountry code="subField">Würzburg</wicri:noCountry></affiliation></author><author><name sortKey="Uberla, K" sort="Uberla, K" uniqKey="Uberla K" first="K." last="Überla">K. Überla</name><affiliation wicri:level="4"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Universität München</wicri:regionArea><placeName><settlement type="city">Munich</settlement><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region></placeName><orgName type="university">Université Louis-et-Maximilien de Munich</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neural Transmission</title><title level="j" type="sub">Basic neurosciences and genetics, Parkinson's disease and allied conditions, Alzheimer's disease and related disorders, biological psychiatry</title><title level="j" type="abbrev">J. Neural Transmission</title><idno type="ISSN">0300-9564</idno><idno type="eISSN">1435-1463</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1996-06-01">1996-06-01</date><biblScope unit="volume">103</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="699">699</biblScope><biblScope unit="page" to="715">715</biblScope></imprint><idno type="ISSN">0300-9564</idno></series><idno type="istex">C1B49CBEEDEF204DF74573AD4429D84F056BF7FC</idno><idno type="DOI">10.1007/BF01271230</idno><idno type="ArticleID">Art6</idno><idno type="ArticleID">BF01271230</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0300-9564</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Long-term levodopa treatment in Parkinson's disease is typically associated with “motor side effects” consisting in dyskinesias and/or fluctuations in motility referred to as the on-off phenomena. The main objective of this prospective, randomized, multi-centre study was to determine to what extent the development of such complications could be prevented by partial substitution of levodopa monotherapy (L-DOPA/benserazide) by bromocriptine in patients with early symptoms of the disease. The basic trial population included 674 newly diagnosed Parkinsonian patients that were randomly allocated to monotherapy with levodopa or a combination therapy based upon a nearly 40% replacement of levodopa by bromocriptine. The two target regimens had to be consistently maintained for 42 months. Parkinsonian symptoms were assessed by means of the Webster rating scale, the Hoehn and Yahr scale, and the Zung Self-Rating Depression scale. Motor side effects and adverse events were recorded at each regular clinic visit. Neurological symptoms improved and stabilized in a similar manner during treatment with both regimens throughout the study period. Motor side effects were observed in more patients on levodopa alone than on combination therapy (28.8 vs 20%; p=0.008). According to Kaplan-Meier estimates the cumulative probability of experiencing motor side effects was 0.43 on monotherapy, compared to 0.28 on combination therapy, which was equal to a one third reduction of risk (p=0.025). In regard to motor side effects, the degree of substitution of levodopa proved relevant: patients with >50% substitution by bromocriptine exhibited half the risk observed in those with <30% (p=0.045). The overall burden of motor side effects, as reflected by a sum score based upon the relevance, the severity and the extent of motor dysfunction, was also significantly less on combination therapy (p=0.046). In conclusion, partial substitution of levodopa by bromocriptine (>30%) as first-line treatment of Parkinson's disease proves active in the prophylaxis of levodopa associated motor side effects. Early combination therapy therefore extends the period of optimal disease control.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Autriche</li></country><region><li>Bavière</li><li>District de Haute-Bavière</li><li>Vienne (Autriche)</li></region><settlement><li>Munich</li><li>Vienne (Autriche)</li></settlement><orgName><li>Université Louis-et-Maximilien de Munich</li></orgName></list><tree><noCountry><name sortKey="Gerlach, M" sort="Gerlach, M" uniqKey="Gerlach M" first="M." last="Gerlach">M. Gerlach</name><name sortKey="Kaiser, J" sort="Kaiser, J" uniqKey="Kaiser " first="-J." last="Kaiser">-J. Kaiser</name><name sortKey="Kraus, H" sort="Kraus, H" uniqKey="Kraus H" first="H." last="Kraus">H. Kraus</name><name sortKey="Przuntek, H" sort="Przuntek, H" uniqKey="Przuntek H" first="H." last="Przuntek">H. Przuntek</name><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Welzel, D" sort="Welzel, D" uniqKey="Welzel D" first="D." last="Welzel">D. Welzel</name></noRegion><name sortKey="Blumner, E" sort="Blumner, E" uniqKey="Blumner E" first="E." last="Blümner">E. Blümner</name><name sortKey="Letzel, H" sort="Letzel, H" uniqKey="Letzel H" first="H." last="Letzel">H. Letzel</name><name sortKey="Uberla, K" sort="Uberla, K" uniqKey="Uberla K" first="K." last="Überla">K. Überla</name></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Danielczyk, W" sort="Danielczyk, W" uniqKey="Danielczyk W" first="W." last="Danielczyk">W. Danielczyk</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002187 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002187 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C1B49CBEEDEF204DF74573AD4429D84F056BF7FC
|texte= Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study
}}
| This area was generated with Dilib version V0.6.23. |  |